JP2012082234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012082234A5 JP2012082234A5 JP2012015831A JP2012015831A JP2012082234A5 JP 2012082234 A5 JP2012082234 A5 JP 2012082234A5 JP 2012015831 A JP2012015831 A JP 2012015831A JP 2012015831 A JP2012015831 A JP 2012015831A JP 2012082234 A5 JP2012082234 A5 JP 2012082234A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- composition
- inhibiting
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 89
- 239000000203 mixture Substances 0.000 claims 42
- 230000002401 inhibitory effect Effects 0.000 claims 37
- 150000003839 salts Chemical class 0.000 claims 30
- 108091000080 Phosphotransferase Proteins 0.000 claims 29
- 201000010099 disease Diseases 0.000 claims 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 29
- 102000020233 phosphotransferase Human genes 0.000 claims 29
- 239000012453 solvate Substances 0.000 claims 28
- 102000001253 Protein Kinase Human genes 0.000 claims 22
- 108060006633 protein kinase Proteins 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 18
- 238000004519 manufacturing process Methods 0.000 claims 17
- 102000003989 Aurora kinases Human genes 0.000 claims 8
- 108090000433 Aurora kinases Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 201000008808 Fibrosarcoma Diseases 0.000 claims 3
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 3
- 208000032612 Glial tumor Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 201000010208 Seminoma Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 201000010175 gallbladder cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 208000007538 neurilemmoma Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 201000008968 osteosarcoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 206010038038 rectal cancer Diseases 0.000 claims 3
- 201000001275 rectum cancer Diseases 0.000 claims 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 208000001608 teratocarcinoma Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000001886 ciliary effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 108010083755 proto-oncogene proteins pim Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72415805P | 2005-10-06 | 2005-10-06 | |
| US60/724,158 | 2005-10-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534673A Division JP5152922B2 (ja) | 2005-10-06 | 2006-10-04 | プロテインキナーゼを阻害するためのピラゾロ[1,5−a]ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014002164A Division JP2014062129A (ja) | 2005-10-06 | 2014-01-09 | プロテインキナーゼを阻害するためのピラゾロ[1,5−a]ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012082234A JP2012082234A (ja) | 2012-04-26 |
| JP2012082234A5 true JP2012082234A5 (OSRAM) | 2012-08-16 |
| JP5520325B2 JP5520325B2 (ja) | 2014-06-11 |
Family
ID=37943366
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534673A Active JP5152922B2 (ja) | 2005-10-06 | 2006-10-04 | プロテインキナーゼを阻害するためのピラゾロ[1,5−a]ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法 |
| JP2012015831A Active JP5520325B2 (ja) | 2005-10-06 | 2012-01-27 | プロテインキナーゼを阻害するためのピラゾロ[1,5−a]ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法 |
| JP2014002164A Pending JP2014062129A (ja) | 2005-10-06 | 2014-01-09 | プロテインキナーゼを阻害するためのピラゾロ[1,5−a]ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534673A Active JP5152922B2 (ja) | 2005-10-06 | 2006-10-04 | プロテインキナーゼを阻害するためのピラゾロ[1,5−a]ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014002164A Pending JP2014062129A (ja) | 2005-10-06 | 2014-01-09 | プロテインキナーゼを阻害するためのピラゾロ[1,5−a]ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20070082900A1 (OSRAM) |
| EP (1) | EP1942900B1 (OSRAM) |
| JP (3) | JP5152922B2 (OSRAM) |
| CN (1) | CN101360499B (OSRAM) |
| BR (1) | BRPI0616985B1 (OSRAM) |
| CA (1) | CA2627623C (OSRAM) |
| NO (1) | NO20082093L (OSRAM) |
| NZ (1) | NZ567151A (OSRAM) |
| TW (1) | TWI421078B (OSRAM) |
| WO (1) | WO2007044441A2 (OSRAM) |
| ZA (1) | ZA200802998B (OSRAM) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7196092B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7563798B2 (en) * | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US7601724B2 (en) * | 2002-09-04 | 2009-10-13 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US8580782B2 (en) * | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| TW200803863A (en) * | 2005-11-10 | 2008-01-16 | Schering Corp | Method for inhibiting protein kinases |
| EP1993552A2 (en) * | 2006-03-08 | 2008-11-26 | Novartis AG | Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders |
| AU2007268083A1 (en) * | 2006-05-22 | 2007-12-06 | Schering Corporation | Pyrazolo [1, 5-A] pyrimidines as CDK inhibitors |
| WO2008063558A2 (en) * | 2006-11-17 | 2008-05-29 | Schering Corporation | Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders |
| TW200845962A (en) | 2007-05-08 | 2008-12-01 | Schering Corp | Methods of treatment using intravenous formulations comprising temozolomide |
| US20120029204A1 (en) * | 2007-06-07 | 2012-02-02 | Schering Corporation | Synthesis of substituted-3-aminopyrazoles |
| US8603998B2 (en) * | 2007-11-07 | 2013-12-10 | Merck Sharp & Dohme Corp. | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| US8841312B2 (en) | 2007-12-19 | 2014-09-23 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| JP5608097B2 (ja) | 2008-01-08 | 2014-10-15 | アレイ バイオファーマ、インコーポレイテッド | キナーゼ阻害薬としてのピロロピリジン |
| US8372842B2 (en) * | 2008-01-09 | 2013-02-12 | Array Biopharma Inc. | Pyrazolopyridines as kinase inhibitors |
| JP5530422B2 (ja) * | 2008-04-07 | 2014-06-25 | アムジエン・インコーポレーテツド | 細胞周期阻害薬としてのgem−二置換およびスピロ環式アミノピリジン/ピリミジン |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| SG10201914059WA (en) * | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| CA2740792C (en) * | 2008-10-31 | 2016-06-21 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| WO2010091808A1 (en) * | 2009-02-13 | 2010-08-19 | Bayer Schering Pharma Aktiengesellschaft | Fused pyrimidines |
| WO2010118207A1 (en) * | 2009-04-09 | 2010-10-14 | Schering Corporation | Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2011028638A1 (en) | 2009-09-04 | 2011-03-10 | Schering Corporation | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| CN102625803A (zh) * | 2009-09-11 | 2012-08-01 | 赛林药物股份有限公司 | 药学上有用的杂环-取代的内酰胺 |
| CA2786377C (en) | 2010-01-05 | 2018-02-27 | Vascular Biogenics Ltd. | Compositions and methods for treating malignant gliomas employing viral vectors encoding a fas-chimera |
| DK2521776T3 (en) * | 2010-01-05 | 2017-02-13 | Vascular Biogenics Ltd | METHODS FOR USING A SPECIFIC ANTI-ANGIOGENT ADENOVIRAL AGENT |
| US9227971B2 (en) | 2010-01-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
| EP2918588B1 (en) | 2010-05-20 | 2017-05-03 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
| MY161199A (en) | 2011-03-23 | 2017-04-14 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
| AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| WO2013039854A1 (en) | 2011-09-15 | 2013-03-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| JP6377068B2 (ja) * | 2012-11-16 | 2018-08-22 | ユニバーシティ・ヘルス・ネットワーク | ピラゾロピリミジン化合物 |
| PT4190786T (pt) | 2012-12-07 | 2025-05-29 | Vertex Pharma | Compostos úteis como inibidores da quinase atr |
| JP2016512239A (ja) | 2013-03-15 | 2016-04-25 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物 |
| JP2016512816A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物 |
| EP2970286A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| JP6095857B2 (ja) * | 2013-11-15 | 2017-03-15 | ユニバーシティ・ヘルス・ネットワーク | ピラゾロピリミジン化合物 |
| CA2932757C (en) | 2013-12-06 | 2023-10-31 | Vertex Pharmaceuticals Incorporated | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
| EP3087069B1 (en) | 2013-12-23 | 2019-01-30 | Norgine B.V. | Compounds useful as ccr9 modulators |
| GB201403093D0 (en) * | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| KR102575125B1 (ko) | 2014-06-05 | 2023-09-07 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 저해제로서 유용한 2-아미노-6-플루오로-n-[5-플루오로-피리딘-3-일]-피라졸로[1,5-a]피리미딘-3-카복스아미드 화합물의 방사성표지된 유도체, 상기 화합물의 제조 및 이의 다양한 고체 형태 |
| RU2736219C2 (ru) | 2014-06-17 | 2020-11-12 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации ингибиторов снк1 и atr |
| US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| GB201517263D0 (en) * | 2015-09-30 | 2015-11-11 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven | Therapeutic agents |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| JP2018534296A (ja) | 2015-10-26 | 2018-11-22 | ロクソ オンコロジー, インコーポレイテッドLoxo Oncology, Inc. | Trk阻害薬耐性がんにおける点変異およびそれに関連する方法 |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| MX386416B (es) | 2016-04-04 | 2025-03-18 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida. |
| HUE063877T2 (hu) | 2016-05-18 | 2024-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| AR110252A1 (es) * | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| EP3658557B1 (en) | 2017-07-28 | 2024-06-05 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| WO2020081508A1 (en) * | 2018-10-15 | 2020-04-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| JP7385658B2 (ja) | 2018-10-30 | 2023-11-22 | クロノス バイオ インコーポレイテッド | Cdk9活性を調節するための化合物、組成物、および方法 |
| CA3122136A1 (en) * | 2018-12-07 | 2021-06-11 | Betta Pharmaceuticals Co., Ltd | Tyrosine kinase inhibitors, compositions and methods there of |
| JP7595582B2 (ja) | 2019-03-26 | 2024-12-06 | ベンティックス バイオサイエンシーズ,インク. | Tyk2偽キナーゼリガンド |
| UA129894C2 (uk) | 2019-11-08 | 2025-09-03 | Вентукс Біосціенціс, Інк. | Ліганди псевдокінази tyk2 |
| PH12022551282A1 (en) | 2019-11-25 | 2023-11-29 | Amgen Inc | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0438730Y2 (OSRAM) * | 1986-03-26 | 1992-09-10 | ||
| JP3039751U (ja) * | 1996-12-09 | 1997-07-31 | 尚子 小園 | 鞄類用補助具 |
| JP2002295682A (ja) * | 2001-03-28 | 2002-10-09 | Yazaki Corp | 防水構造およびこの防水構造に用いられる座金部材 |
| CA2487211C (en) * | 2002-06-04 | 2010-09-14 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo(1,5a) pyrimidine compounds as antiviral agents |
| US7196092B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| JP4881558B2 (ja) * | 2002-09-04 | 2012-02-22 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン |
| US7601724B2 (en) * | 2002-09-04 | 2009-10-13 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| MXPA05002573A (es) * | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| AU2004215481B2 (en) * | 2003-02-28 | 2010-11-11 | Teijin Pharma Limited | Pyrazolo(1,5-A)pyrimidine derivatives |
| US20070179161A1 (en) * | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
| JP3940700B2 (ja) * | 2003-05-22 | 2007-07-04 | 茂 相馬 | 楽器用ケース |
| PE20051089A1 (es) * | 2004-01-22 | 2006-01-25 | Novartis Ag | Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina |
| JP3104094U (ja) * | 2004-03-18 | 2004-09-02 | チャン ホアン−リン | 両用スーツケース |
| US7642266B2 (en) * | 2005-10-06 | 2010-01-05 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| ATE533770T1 (de) * | 2005-10-06 | 2011-12-15 | Schering Corp | Pyrazolopyrimidine als proteinkinaseinhibitoren |
| JP3174645U (ja) * | 2012-01-19 | 2012-03-29 | 株式会社セイバン | ランドセル |
-
2006
- 2006-10-04 BR BRPI0616985-6A patent/BRPI0616985B1/pt active IP Right Grant
- 2006-10-04 JP JP2008534673A patent/JP5152922B2/ja active Active
- 2006-10-04 CA CA2627623A patent/CA2627623C/en active Active
- 2006-10-04 TW TW095136818A patent/TWI421078B/zh not_active IP Right Cessation
- 2006-10-04 CN CN200680045935.5A patent/CN101360499B/zh active Active
- 2006-10-04 WO PCT/US2006/038917 patent/WO2007044441A2/en not_active Ceased
- 2006-10-04 US US11/542,801 patent/US20070082900A1/en not_active Abandoned
- 2006-10-04 NZ NZ567151A patent/NZ567151A/en not_active IP Right Cessation
- 2006-10-04 EP EP06836185.6A patent/EP1942900B1/en active Active
-
2008
- 2008-04-04 ZA ZA200802998A patent/ZA200802998B/xx unknown
- 2008-05-05 NO NO20082093A patent/NO20082093L/no not_active Application Discontinuation
-
2010
- 2010-01-15 US US12/688,664 patent/US8211854B2/en active Active
-
2012
- 2012-01-27 JP JP2012015831A patent/JP5520325B2/ja active Active
-
2014
- 2014-01-09 JP JP2014002164A patent/JP2014062129A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012082234A5 (OSRAM) | ||
| JP2018516917A5 (OSRAM) | ||
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2016510028A5 (OSRAM) | ||
| JP2022017295A5 (OSRAM) | ||
| JP2015533176A5 (OSRAM) | ||
| JP2014518544A5 (OSRAM) | ||
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| NZ597252A (en) | Compounds for inhibiting mitotic progression | |
| HRP20171727T1 (hr) | Novi terapeutici | |
| JP2016536286A5 (OSRAM) | ||
| JP2015193630A5 (OSRAM) | ||
| JP2014512356A5 (OSRAM) | ||
| JP2016522202A5 (OSRAM) | ||
| JP2013504582A5 (OSRAM) | ||
| JP2018534289A5 (OSRAM) | ||
| JP2012528099A (ja) | Plk1阻害剤および抗腫瘍剤を含む治療組合せ | |
| JP2016504325A5 (OSRAM) | ||
| JP2009506054A5 (OSRAM) | ||
| JP2019506392A5 (OSRAM) | ||
| JP2013544892A5 (OSRAM) | ||
| JP2014530181A5 (OSRAM) | ||
| JP2015518053A5 (OSRAM) | ||
| JP2018519300A5 (OSRAM) | ||
| JP2015507020A5 (OSRAM) |